Hisashi Hidaka

Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells.

Takashi Chijiwa, Akihiko Mishima, Masatoshi Hagiwara et al. · Journal of Biological Chemistry · 1990 · 1.5K citations · Full text

Life Sciences, Biochemistry, Pharmacology +14

KN-62, 1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazi ne, a specific inhibitor of Ca2+/calmodulin-dependent protein kinase II.

Hiroshi Tokumitsu, Takashi Chijiwa, Masatoshi Hagiwara et al. · Journal of Biological Chemistry · 1990 · 625 citations · Full text

Life Sciences, Biochemistry, Pharmacology +15

N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide, a calmodulin antagonist, inhibits cell proliferation.

Hisashi Hidaka, Yasuharu Sasaki, Toshio Tanaka et al. · Proceedings of the National Academy of Sciences · 1981 · 586 citations · Full text

Life Sciences, Cell Biology, Pharmacology +15

Selective inhibition of catalytic activity of smooth muscle myosin light chain kinase.

M. Saitoh, Tomohiko Ishikawa, S Matsushima et al. · Journal of Biological Chemistry · 1987 · 512 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +7

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Shukui Qin, Minshan Chen, Ann‐Lii Cheng et al. · The Lancet · 2023 · 488 citations · Full text

Medicine, Oncology, Pharmacotherapy +14